您的当前位置:首页 > 行业数据 > 中国已获批及在研的IL-4R和针对特应性皮炎的JAK靶点药物(不含生物类似物和仿
图片属性
图片格式:PNG 图片大小:472KB 图片尺寸:2303*2625
同报告图片
 / 4
中国已获批及在研的IL-4R和针对特应性皮炎的JAK靶点药物(不含生物类似物和仿_第1页
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
中国已获批及在研的IL-4R和针对特应性皮炎的JAK靶点药物(不含生物类似物和仿_第2页
fCDlubTku70gfCDluILlnLrku73pop0gfAp8LS0tLS0tfC0tLS0tLS0tLS18CnwgMjAxOSB8IDY2LjMlICAgIHwKfCAyMDIwIHwgNzUuMCUgICAgfAp8IDIwMjEgfCA3MS4yJSAgICB8CnwgMjAyMiB8IDcxLjclICAgIHwKfCAyMDIzIHwgNzIuNiUgICAgfAoK6LWE5paZ5p2l5rqQ77ya5LiJ55Sf5Yi26I2v77yM5oub6ZO25Zu96ZmF546v55CD5biC5Zy6
中国已获批及在研的IL-4R和针对特应性皮炎的JAK靶点药物(不含生物类似物和仿_第3页
中国已获批及在研的IL-4R和针对特应性皮炎的JAK靶点药物(不含生物类似物和仿_第4页
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
中国已获批及在研的IL-4R和针对特应性皮炎的JAK靶点药物(不含生物类似物和仿_第5页
所属报告: 三生制药-港股公司研究报告-核心品种增长稳健创新产品迎来收获;首予买入-240809(49页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠